Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ajcp/aqaa123 http://scihub22266oqcxt.onion/10.1093/ajcp/aqaa123 32666092!7454292!32666092     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Clin+Pathol 2020 ; 154 (4): 459-465 Nephropedia Template TP {{tp|p=32666092|t=2020. SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity |pdf=|usr=}}{{32666092}} gab.com Text SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity JO: Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=32666092 #FOAvip OBJECTIVES: Initial reports indicate adequate performance of some serology-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course. METHODS: A total of 967 subjects were tested for IgG antibodies reactive to SARS-CoV-2, including 172 suspected cases of SARS-CoV-2, 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for polymerase chain reaction (PCR)-based respiratory viral panel. A subgroup of SARS-CoV-2 PCR-positive cases was tested for IgM antibodies by proteome array method. RESULTS: All specificity and cross-reactivity specimens were negative for SARS-CoV-2 IgG antibodies (0/795, 0%). Positive agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from symptom onset, with less than 100% sensitivity attributable to a case with severe immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course with respect to IgG and IgM levels. CONCLUSIONS: The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse cross-reactivity. Measures of IgG and IgM antibodies did not predict disease severity in our patient population. Twit Text FOAVip SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity ????Am J Clin Pathol http://www.kidney.de/pget.php?&tw=1&pmid=32666092 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32666092 #FOAvip English Wikipedia <ref>{{Cite pmid|32666092}}</ref> SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity #MMPMID32666092 Phipps WS; SoRelle JA; Li QZ; Mahimainathan L; Araj E; Markantonis J; Lacelle C; Balani J; Parikh H; Solow EB; Karp DR; Sarode R; Muthukumar A Am J Clin Pathol 2020[Sep]; 154 (4): 459-465 PMID32666092show ga OBJECTIVES: Initial reports indicate adequate performance of some serology-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assays. However, additional studies are required to facilitate interpretation of results, including how antibody levels impact immunity and disease course. METHODS: A total of 967 subjects were tested for IgG antibodies reactive to SARS-CoV-2, including 172 suspected cases of SARS-CoV-2, 656 plasma samples from healthy donors, 49 sera from patients with rheumatic disease, and 90 specimens from individuals positive for polymerase chain reaction (PCR)-based respiratory viral panel. A subgroup of SARS-CoV-2 PCR-positive cases was tested for IgM antibodies by proteome array method. RESULTS: All specificity and cross-reactivity specimens were negative for SARS-CoV-2 IgG antibodies (0/795, 0%). Positive agreement of IgG with PCR was 83% of samples confirmed to be more than 14 days from symptom onset, with less than 100% sensitivity attributable to a case with severe immunosuppression. Virus-specific IgM was positive in a higher proportion of cases less than 3 days from symptom onset. No association was observed between mild and severe disease course with respect to IgG and IgM levels. CONCLUSIONS: The studied SARS-CoV-2 IgG assay had 100% specificity and no adverse cross-reactivity. Measures of IgG and IgM antibodies did not predict disease severity in our patient population. |*Clinical Laboratory Techniques[MESH] |*Severity of Illness Index[MESH] |Antibodies, Viral/*blood[MESH] |Antibody Formation[MESH] |Betacoronavirus/*immunology[MESH] |Biomarkers/blood[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Case-Control Studies[MESH] |Coronavirus Infections/blood/*diagnosis/*immunology[MESH] |Cross Reactions[MESH] |Cross-Sectional Studies[MESH] |Humans[MESH] |Immunoglobulin G/*blood[MESH] |Immunoglobulin M/blood[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/*diagnosis/*immunology[MESH] |SARS-CoV-2[MESH]SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity(epmc).pdf DeepDyve Pubget Overpricing